Evolent Health Inc Class A Stock News

WASHINGTON, Jan. 2, 2026 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH) ("Evolent" or the "Company"), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, announced that the Compensation Committee of Evolent's Board of Directors approved the grant of a one-time time-based restricted ...

Evolent Health, Inc. ( EVH ) UBS Global Healthcare Conference 2025 November 11, 2025 5:00 PM EST Company Participants John Johnson - Chief Financial Officer Conference Call Participants Kevin Caliendo - UBS Investment Bank, Research Division Presentation Kevin Caliendo UBS Investment Bank, Research Division Good afternoon. This is Kevin Caliendo, health care service and distribution and IT anal...

Evolent Health, Inc. ( EVH ) Q3 2025 Earnings Call November 6, 2025 5:00 PM EST Company Participants Seth Blackley - Co-Founder, CEO & Director John Johnson - Chief Financial Officer Conference Call Participants Kevin Caliendo - UBS Investment Bank, Research Division Daniel Grosslight - Citigroup Inc., Research Division John Stansel - JPMorgan Chase & Co, Research Division Lucas Romanski - TD C...

WASHINGTON , Nov. 6, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company focused on achieving better health outcomes for people with complex conditions, and American Oncology Network (AON), one of the nation's fastest-growing community oncology networks, today announced a new model enabling high-quality, more affordable, and connected cancer care — all without relying on prior auth...

Q3 2025 financial results ahead of expectations. Announces more than $500 million in newly-contracted annualized revenue to launch in 2026.

Company to Participate in Upcoming Conferences WASHINGTON , Oct. 9, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company focused on achieving better health outcomes for people with complex conditions, today announced it will release its third quarter 2025 financial results on Thursday, November 6, 2025, after market close, with a conference call to follow at 5 p.m. ET. Shareholders ...

Transaction enhances focus on specialty condition management and accelerates Evolent's deleveraging path. Proceeds from the transaction to be used to prepay senior term debt; Immediately accretive to Evolent's free cash flow by more than $7 million per year.

Evolent's revenue dip in Q1 was structural, not demand-driven, and Q2 shows stabilization; I expect growth to resume in the second half of 2025. New specialty contracts, incremental member growth, and key leadership appointments should drive recovery and enhance clinical and financial credibility. The oversubscribed convertible notes offering signals investor confidence, strengthens liquidity, ...